semaglutide versions Novo Nordisk launched an oral version of its GLP-1 injectable to US markets on Jan 5. Link in comments Novo Nordisk sues spas and

Gut Health Support Helps repair the stomach and intestinal lining to improve digestive function

CB-839 is a highly potent allosteric inhibitor that completed phase I clinical trials in March 2019 in patients with advanced RCC (NCT02071862) and has in 2020 moved to phase II clinical trials in patients with non-small cell lung cancer (NCT04265534)

Fatigue is a labeled adverse reaction for some products (e.g., Wegovy) and may relate to reduced caloric intake, adjustment to metabolic changes, or direct medication effects

UTI-Related Pain and Spasms: Combined with other agents, MB helps relieve discomfort from UTIs

It also demonstrates antimicrobial properties against common pathogens